Preparation and identification of an anti-idiotypic antibody antagonist (FG8) for EGFR that shows potential activity against liver cancer cells
Autor: | Ying Cao, Aliya Rehati, Helin Zhang, Yurong Wang, Yaqing Zhang, Fangping He, Yun Ling |
---|---|
Rok vydání: | 2020 |
Předmět: |
0106 biological sciences
0301 basic medicine Antineoplastic Agents Apoptosis Enzyme-Linked Immunosorbent Assay Bioengineering Immunofluorescence Binding Competitive 01 natural sciences Applied Microbiology and Biotechnology Epitope Epitopes 03 medical and health sciences Antigen Cell Line Tumor 010608 biotechnology medicine Humans Epidermal growth factor receptor Cell Proliferation medicine.diagnostic_test biology Chemistry Cell growth Liver Neoplasms General Medicine Antibodies Anti-Idiotypic ErbB Receptors 030104 developmental biology Cancer research biology.protein Hybridoma technology Antibody Signal transduction Protein Binding Signal Transduction Biotechnology |
Zdroj: | Biotechnology Letters. 43:369-382 |
ISSN: | 1573-6776 0141-5492 |
DOI: | 10.1007/s10529-020-03017-6 |
Popis: | Currently, there are two categories of epidermal growth factor receptor (EGFR) antagonists, small molecule antagonists and anti-EGFR antibodies. In the current study, we developed a new EGFR antagonist employing the anti-idiotypic antibodies strategy. First, using EGF as an antigen, through a series of immunological protocols and hybridoma technology, we obtained an anti-idiotypic antibody against EGF receptor-binding epitopes. On this basis, we screened and characterized the anti-idiotype antibodies against EGFR through competitive ELISA, co-localization analysis, competitive receptor binding analysis, and immunofluorescence. Finally, an internal image anti-idiotype antibody called FG8 was successfully prepared. Experiment result shows that FG8 inhibits EGFR-mediated signaling pathways in vitro. Additionally, FG8 inhibits liver tumor cell proliferation as well as induces tumor cell apoptosis. The present study suggests that FG8 is a potential therapeutic agent for liver cancer. In addition, this study provides a novel method for the preparation of EGFR antagonists. |
Databáze: | OpenAIRE |
Externí odkaz: |